REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology firm creating focused therapies for RAS-addicted cancers, at this time introduced that Mark A. Goldsmith, M.D., Ph.D., the corporate’s chief government officer and chairman, will probably be a featured speaker at Guggenheim’s Inaugural Healthcare Innovation Convention and the UBS International Healthcare Convention.
Particulars of the corporate’s participation are as follows:
- Guggenheim’s Inaugural Healthcare Innovation Convention
Convention Dates: November 11-13, 2024
Fireplace Chat Time/Date: 3:00 p.m. ET on Tuesday, November 12, 2024
Location: Boston, MA; webcast accessible
- UBS International Healthcare Convention
Convention Dates: November 11-14, 2024
Fireplace Chat Time/Date: 5:00 p.m. ET on Wednesday, November 13, 2024
Location: Rancho Palos Verdes, CA; webcast accessible
To entry the reside webcasts, please go to the Occasions & Shows web page of Revolution Medicines’ web site at https://ir.revmed.com/events-and-presentations. Moreover, a replay of the webcasts will probably be accessible on the Occasions & Shows web page of the Revolution Medicines web site for no less than 14 days following the convention.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology firm creating novel focused therapies for RAS-addicted cancers. The corporate’s R&D pipeline contains RAS(ON) inhibitors designed to suppress numerous oncogenic variants of RAS proteins. The corporate’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are presently in medical improvement. Further improvement alternatives within the firm’s pipeline deal with RAS(ON) mutant-selective inhibitors, together with RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), along with RAS companion inhibitors RMC-4630 and RMC-5552.
Media & Investor Contacts:media@revmed.cominvestors@revmed.com
Supply: Revolution Medicines, Inc.
